US National Cancer Institute awards grant to Apogee for YELIVA prostate cancer research
In March 2015, RedHill Biopharma acquired from Apogee the exclusive worldwide rights to YELIVA (ABC294640), a first-in-class, orally-administered sphingosine kinase-2 ("SK2") selective inhibitor. Following prior pre-clinical studies in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.